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Exclusion of a Brain Lesion: Is Intravenous Contrast
Administration Required after Normal Precontrast Magnetic
Resonance Imaging?
E.J. Ives, N. Rousset, N. Heliczer, M.E. Herrtage, and A.E. Vanhaesebrouck
Background: No evidence-based guidelines are available for the administration of gadolinium-based contrast media to
veterinary patients.
Objective: To investigate whether administration of intravenous (IV) contrast media alters the likelihood of identifying
a brain lesion in dogs and cats.
Animals: Four hundred and eighty-seven client-owned animals referred for investigation of intracranial disease.
Methods: Two reviewers retrospectively analyzed precontrast transverse and sagittal T1-weighted (T1W), T2-weighted,
and ﬂuid-attenuated inversion recovery low-ﬁeld MRI sequences from each patient for the presence of a clinically relevant
brain lesion. All sequences subsequently were reviewed in the same manner with additional access to postcontrast T1W images.
Results: Of the 487 precontrast MRI studies, 312 were judged to be normal by 1 or both reviewers. Of these 312 studies,
a previously undetected lesion was identiﬁed in only 6 cases (1.9%) based on changes observed on postcontrast sequences.
Final diagnoses included meningoencephalitis of unknown origin (n = 1), feline infectious peritonitis (n = 1), and neoplasia
(n = 2). All 4 of these cases had persistent neurological deﬁcits suggestive of an underlying brain lesion. Contrast enhance-
ment observed in the 2 other cases was considered falsely positive based on the results of further investigations.
Conclusions and Clinical Importance: In patients with normal neurological examination and normal precontrast MRI,
the subsequent administration of IV gadolinium-based contrast media is highly unlikely to disclose a previously unidenti-
ﬁed lesion, calling into question the routine administration of contrast media to these patients. However, administration
still should be considered in animals with persistent neurological deﬁcits suggestive of an underlying inﬂammatory or
neoplastic brain lesion.
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Chelates of gadolinium are the most commonly usedIV contrast media in magnetic resonance imaging
(MRI). Their administration has been widespread in
both human and veterinary medicine since gadopente-
tate dimeglumine ﬁrst became available for clinical use
in 1988.1 Gadolinium-based contrast media act as para-
magnetic substances, shortening the T1-relaxation time
of adjacent protons with resultant hyperintensity at
regions of contrast media accumulation on subsequent
imaging.2 Contrast accumulation may occur in patho-
logical tissues because of disruption of the blood–brain
barrier, vasodilatation or neovascularization.2,3
The ﬁndings observed on postcontrast sequences
may assist in the further characterization of a brain
lesion observed on precontrast sequences.3–5 However,
the routine administration of gadolinium-based con-
trast media has been questioned for human patients,
especially if no lesion is observed on precontrast
sequences.6 Suspected adverse reactions related to
administration of these agents have been reported in
humans and dogs,7–12 and both increased scanning
time and duration of general anesthesia, together with
their associated costs, also should be considered.
No evidence-based guidelines currently exist for the
IV administration of gadolinium-based contrast media
to veterinary patients. The aim of this study was to
determine whether the absence of a visible lesion on
precontrast T1-weighted (T1W), T2-weighted (T2W),
and T2W-ﬂuid-attenuated inversion recovery (FLAIR)
sequences can exclude the presence of MRI-detectable
intracranial pathology, thus questioning routine IV
administration of contrast media to these patients.
Materials and Methods
Case Selection
A retrospective search of the MRI database at The Queen’s
Veterinary School Hospital, University of Cambridge, United
Kingdom was performed for all brain MRI scans of dogs or cats
acquired between March 2004 and June 2012. Cases were
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Abbreviations:
CNS central nervous system
CSF cerebrospinal ﬂuid
CT computed tomography
FLAIR ﬂuid-attenuated inversion recovery
MRI magnetic resonance imaging
T Tesla
T1W T1-weighted
T2W T2-weighted
TE echo time
TR repetition time
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included if precontrast transverse and sagittal T1W and T2W
images, transverse FLAIR images, and postcontrast transverse
and sagittal T1W images were acquired. Any additional image
planes or sequences were excluded from the analysis.
To match the normal clinical environment at the authors’
institution, clinical data for each patient were extracted from
the original radiology request form and were available to each
reviewer at the time of image analysis. These data included
species, breed, age at the time of imaging, sex, and the indica-
tion(s) for imaging. The indications for imaging were grouped
into categories of presenting clinical signs based upon the ﬁnd-
ings of complete general clinical and neurological examinations
performed by a board-certiﬁed neurologist in all cases
(Table 1).
All data were acquired and entered into a spreadsheet format
using commercial software.a Case selection and data acquisition
were performed by 2 investigators not involved in the image
analysis (EI, NH).
Magnetic Resonance (MR) Imaging
All imaging was performed under general anesthesia at the
authors’ institution using a 0.2 Tesla (T) permanent magnetb
before October 2008 and a 0.23 T permanent magnet after
that time.c MR images of the brain were acquired using diﬀer-
ent transmitter-receiver coils dependent on the patient’s head
size. Acquisition parameters for each sequence were as follows:
T1W repetition time (TR) 600–800 ms, echo time (TE) 18–
26 ms; T2W TR 2,800–3,000 ms, TE 80 ms; FLAIR TR
5,840–7,000 ms, TR 80 ms. Slice thickness for all sequences
was 4 mm. Contrast studies were performed immediately after
IV bolus administration of 0.1 mmol/kg gadobenate dimeglu-
mined before October 2008 and 0.1 mmol/kg gadobutrol after
that time.e
Image Analysis
For each case, precontrast sagittal and transverse T1W and
T2W images and transverse FLAIR images were analyzed inde-
pendently by a board-certiﬁed neurologist (AV) and a third-year
European College of Veterinary Diagnostic Imaging residency-
trained radiologist (NR) using digital imaging software.f If a
lesion was identiﬁed, each reviewer was asked to specify in which
sequence(s) it was visible. A clinically relevant lesion was deﬁned
as a structural abnormality, mass lesion, abnormal signal inten-
sity or some combination of these that could account for the
indication for imaging. At the reviewer’s discretion, changes
observed could be classiﬁed as incidental if deemed artifactual,
breed-related or incompatible with the presenting signs. These
changes included mild ventricular asymmetry in the absence of a
mass eﬀect, bilateral T2W hyperintensity of the piriform lobes if
deemed postictal, and mild cerebellar herniation in conjunction
with Chiari-like malformation in breeds such as the Cavalier
King Charles Spaniel. A case was determined to have a normal
precontrast MRI study if no lesion was observed on T1W, T2W,
and FLAIR sequences to account for the indication for imaging.
If a clinically relevant lesion was observed on ≥1 of the sequences
above, then the precontrast assessment was classiﬁed as abnormal
by that reviewer.
Three months after initial assessment, a second analysis was
performed for all cases by the same reviewers, but with the addi-
tional inclusion of sagittal and transverse T1W images acquired
after administration of gadolinium-based contrast media. Con-
trast enhancement of the pituitary gland, choroid plexus or
trigeminal nerves could be rated as nonpathologic if deemed
within normal limits.13,14 Reviewers were asked to indicate if any
abnormal contrast enhancement was visible on postcontrast
sequences and to classify the entire study, with access to all
sequences, as either normal or abnormal based on the presence
of a clinically relevant brain lesion.
Acquisition of Additional Clinical Data
The results of further investigations (including hematology,
serum biochemistry, cerebrospinal ﬂuid analysis [CSF] and histo-
pathologic data when available), follow-up information, and the
ﬁnal presumptive or deﬁnitive clinical diagnoses, were retrieved
from the clinical records for all MRI studies that either reviewer
had rated as normal during the ﬁrst assessment, but had subse-
quently rated as abnormal after additional access to postcontrast
images.
Results
Study Population
The initial database search identiﬁed 551 brain MRI
studies that fulﬁlled the inclusion criteria. Sixty-four
studies subsequently were excluded because of inade-
quate medical records or lack of access to all
sequences. Four hundred and eighty-seven cases were
available for complete analysis, comprising 433 dogs
and 54 cats.
Median age for the dogs was 6 years (range,
3 months to 15 years), with 247 male (57%) and 186
female (43%) dogs. Breeds represented included Lab-
rador Retriever (n = 56, 13%), Boxer (n = 36, 8.3%),
mixed breed (n = 34, 7.9%), German Shepherd
(n = 25, 5.8%), Border Collie (n = 22, 5.1%), and 60
other breeds with ≤20 dogs each.
Median age for the cats was 7 years (range,
4 months to 16 years) with 31 male (57%) and 23
female (43%) cats. Breeds represented included
Domestic Shorthair (n = 26, 48%), Domestic Longhair
(n = 7, 13%), British Shorthair (n = 7, 13%), and 9
other breeds with ≤2 cats each.
Table 1. Categorized indications for imaging.
Indication for Imaging
Number
of Dogs
Number
of Cats
Total
Number (%
of Total)
Seizures 227 20 247 (51)
Behavior change 65 12 77 (16)
Vestibular signs 59 12 71 (15)
Ataxia 39 9 48 (10)
Reduced level of mentation 36 4 40 (8)
Cranial nerve deﬁcits 38 1 39 (8)
Paresis 24 6 30 (6)
Blindness 22 7 29 (6)
Polyuria/polydipsia 21 2 23 (5)
Collapsing episodes 12 1 13 (3)
Anisocoria 8 3 11 (2)
Cerebellar signs 7 1 8 (2)
Tremors 6 2 8 (2)
Postural reaction deﬁcits 5 2 7 (1)
Multifocal central
nervous system signs
3 – 3 (1)
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The categorized indications for imaging and the
numbers of animals for which each category was appli-
cable are summarized in Table 1.
Precontrast Assessment
A total of 281 cases (58%) were deemed to have
normal precontrast MRI studies by both reviewers. A
clinically relevant lesion was observed in 175 cases
(36%) by both reviewers. A single reviewer reported a
normal precontrast MRI study in an additional 31
cases (6%), resulting in overall interobserver agreement
of 94%.
Assessment after Inclusion of Postcontrast
Sequences
A total of 288 cases (59%) were deemed to have a
normal complete MRI study by both reviewers. A clin-
ically relevant lesion was identiﬁed in 177 cases (36%)
by both reviewers. A single reviewer reported a normal
MRI study in the additional 22 cases (5%), resulting
in interobserver agreement of 95%.
Identification of a Lesion Only on Postcontrast
Images
Of the 312 cases rated as normal by either 1 (31 cases)
or both reviewers (281 cases) at precontrast assessment,
a previously undetected lesion was observed in only 6
cases (1.9%) on postcontrast sequences (in 5 cases by a
single reviewer and in 1 case by both reviewers). Four of
these cases had persistent neurological deﬁcits on exami-
nation consistent with the lesion identiﬁed on postcon-
trast images. Diagnoses in these cases included
meningoencephalitis of unknown origin in a 2-year-old
dog with a mononuclear CSF pleocytosis, and a sus-
pected basal meningioma in a 10-year-old dog with
blindness. Feline infectious peritonitis and cranial nerve
T-cell lymphoma in an 8-year-old dog were conﬁrmed
by postmortem histopathology and CSF ﬂow cytome-
try, respectively, in 2 additional cases. Based on results
of CSF analysis and subsequent disease course, the
remaining 2 cases appeared to represent false positives
after observed meningeal contrast enhancement. Final
clinical diagnoses included idiopathic epilepsy in a cat
and suspected cerebellar cortical degeneration in a
young dog.
Identification of a Previously Undetected Lesion on
Precontrast T1W, T2W, or FLAIR Images
In 3 dogs (1%), a lesion was identiﬁed subsequently
by 1 reviewer on precontrast T1W, T2W, or FLAIR
sequences (with no visible contrast enhancement) that
had not been identiﬁed previously during the ﬁrst
assessment. The ﬁnal clinical diagnoses for these cases
were suspected neuraxonal dystrophy based on signal-
ment, presenting clinical signs and MRI appearance; a
small suspected forebrain glioma; and L-2-hydroxyglu-
taric aciduria conﬁrmed by genetic testing.
Discussion
The results of this study indicate that if no brain
lesion is observed on routine T1W, T2W, and FLAIR
sequences, then the likelihood of identifying an abnor-
mality on postcontrast sequences is low (1.9%). This
questions the routine IV administration of contrast
media in this situation.
Whereas this is the ﬁrst study to speciﬁcally assess
this dilemma for MRI in veterinary medicine, a num-
ber of studies have investigated the diagnostic role of
gadolinium-based contrast media in human medicine.
These studies report similar ﬁndings to the present
study, with a previously unidentiﬁed lesion seen in
only 3% of human patients after contrast administra-
tion when compared to precontrast T1W and T2W
images.15 When MRI was used to investigate seizure
etiology in children <2 years of age, contrast media
was judged essential in only 1.8% of cases, with intra-
cranial infectious processes demonstrated or highly
suspected in all cases.16 Another report stated that IV
administration of gadolinium-based contrast media
may be unnecessary in human patients after negative
precontrast FLAIR imaging.6 This conclusion was
based upon improved sensitivity of MRI for lesion
detection from 99.5% using FLAIR images alone to
99.6% after inclusion of postcontrast sequences. Previ-
ous studies in humans also have suggested that nega-
tive FLAIR images may eliminate the need for
gadolinium-enhanced T1W images in the diagnosis of
intracranial infections,17 leptomeningeal disease,18 and
in the detection of intracranial tumors.19,20 However, a
critical review of the human literature concluded that
despite the widespread use of MR contrast media, no
rigorous studies existed to establish a solid evidence
base for their application in human medicine.1
The ﬁndings of this study also are similar to those
reported for computed tomography (CT) of the brain
in both human and equine patients. It has been
reported that if the unenhanced CT scan is normal,
then subsequent contrast administration may result in
identiﬁcation of an abnormality in only 0.5–2.7% of
cases.21–24 Published guidelines for cranial CT in
human medicine conclude that it is reasonable not to
administer IV contrast if there are no persistent neuro-
logical deﬁcits and if the unenhanced scan is normal.22
The cases for which a brain lesion was identiﬁed
only on postcontrast images in this study warrant fur-
ther discussion. Although the small number of cases
for which contrast was essential for lesion detection
precluded statistical analysis, there was no suggestion
that patient signalment should inﬂuence the decision
on whether or not to administer IV contrast. However,
the results show support for the administration of con-
trast media to patients with persistent neurological def-
icits that are consistent with the presence of a central
nervous system (CNS) inﬂammatory or infectious dis-
ease.
The recommendation for the routine use of contrast
media in the suspicion of CNS inﬂammatory disease
still would apply if CSF sampling were planned
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because CSF analysis may be normal in up to 10% of
patients with an underlying CNS inﬂammatory disor-
der.25 A previous veterinary study compared the sensi-
tivity of diﬀerent MRI sequences for the detection of
multifocal intracranial disease and found FLAIR
sequences to be the most sensitive when compared to
T1W, T2W, and contrast-enhanced T1W sequences.
However, the study also showed support for continued
use of contrast-enhanced sequences in the investigation
of this subset of patients, with 4% of dogs having
MRI changes visible only after contrast administra-
tion.26 Another study of 25 dogs with an inﬂammatory
CSF sample reported that contrast administration
identiﬁed the presence of a previously occult lesion in
8 of these cases.27
The results of this study also suggest that gadolin-
ium-based contrast media may be of beneﬁt in the iden-
tiﬁcation of certain intracranial neoplasms, especially if
involving the cranial nerves or if too small to result in
appreciable mass eﬀect, as seen for the case with a sus-
pected meningioma in this study. In agreement with
these ﬁndings, several authors continue to support the
use of MRI contrast media in the detection of cerebral
metastasis in humans.28,29 However, lack of contrast
enhancement does not exclude the presence of meta-
static disease, as recently reported in a dog with meta-
static cerebral adenocarcinoma.30 The reason for lack
of enhancement in this case was unknown, but sugges-
tions included a combination of prior corticosteroid
administration and increased intracranial pressure, in
the presence of highly diﬀerentiated metastases.
Excluding the cat with a ﬁnal diagnosis of suspected
idiopathic epilepsy, all cases for which contrast admin-
istration was essential for lesion detection had neuro-
logical deﬁcits on initial examination suggestive of an
underlying pathologic lesion. It would appear therefore
that for animals with neurolocalization of intracranial
disease, but without persistent neurological deﬁcits on
examination, the IV administration of contrast media
to patients with negative precontrast imaging is highly
unlikely to identify a previously undetected abnormal-
ity. However, lesion localization and determination of
both a normal neurological examination and negative
precontrast imaging should be based upon careful
examination of the animal and precontrast images by
suitably trained and experienced neurologists and radi-
ologists before the decision not to administer contrast
is made. This approach will avoid, wherever possible,
a situation where a repeated MRI scan may be
required at a later date, with associated costs and the
risk of repeated general anesthesia. This approach
requires real-time review of precontrast imaging by a
radiologist, which may not be possible in all situations.
Two of the cases for which a previously undetected
lesion was observed after contrast administration
appeared to represent false positives. Diﬀuse meningeal
enhancement was observed during analysis in both
cases, resulting in suspicion of meningitis to explain
the indication for imaging. The subjective nature in
diﬀerentiation between pathologic and nonpathologic
meningeal enhancement is likely to account for these
false positive results.
The purpose of this study was to compare the likeli-
hood of lesion identiﬁcation before and after IV
administration of contrast media, and it does not chal-
lenge the view that the degree or pattern of contrast
uptake may assist in the further characterization of a
lesion already observed on precontrast images. In both
human and veterinary medicine, the pattern of con-
trast enhancement has been used to evaluate tumor
type,4,5 predict seizure risk in cases of intracranial neo-
plasia,31 and diﬀerentiate neoplastic from non-neoplas-
tic lesions, such as postoperative scar tissue,
irradiation injury, inﬂammation or cerebrovascular
lesions.3,32,33 However, contrast enhancement patterns
do not consistently reﬂect the histologic features of an
intracranial lesion, with no association between MR
images and histologic ﬁndings in approximately 25%
of cases in 1 veterinary study.34
An important factor to consider before administra-
tion of any substance is the potential for adverse
eﬀects. The reported incidence of adverse reactions
after administration of gadolinium-based contrast
agents to humans ranges from 0.004 to 5%.7–11 The
most frequent complaints include rashes, abnormal
sensations at the injection site, nausea or vomiting,
anxiety and headaches.7–11 However, severe late reac-
tions, such as nephrogenic systemic ﬁbrosis, also may
be seen.35 Severe anaphylactoid reactions are estimated
to occur in approximately 0.01% of human patients,7
with a mortality rate of 0.0007–0.0019%.10,36 Many of
the more frequent, mild reactions may be diﬃcult to
recognize in veterinary patients, especially given the
routine use of general anesthesia for MRI in veterinary
medicine. There are few reports on the incidence of
gadolinium-associated adverse reactions in veterinary
medicine. One report described suspected anaphylac-
toid reactions in 3 dogs, comprising 0.2% of animals
given contrast over this time period.12 Other studies
assessing the potential cardiovascular37–39 and serum
biochemical eﬀects40,41 of contrast administration to
dogs have found no clear association between adminis-
tration of these agents and adverse eﬀects. In addition
to the potential for adverse reactions, the prolongation
of both scanning time and general anesthesia associ-
ated with the acquisition of postcontrast sequences
also should be considered. This consideration is likely
to be more relevant for low-ﬁeld MRI, given the
longer scan times when compared to high-ﬁeld
imaging.
Limitations of this study include the use of previ-
ously acquired scans rather than a randomized pro-
spective study. However, the analysis of scans acquired
during a time when gadolinium-based contrast media
were routinely used at the authors’ institution
decreases the potential for case selection bias. The
inclusion of clinical data for each case may have
biased reviewer expectation as to the potential for a
lesion to be present. However, a recent study found
equivalent interreviewer agreement with or without
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provision of clinical data for detection of brain lesions
in dogs.33
The lack of a histopathologic diagnosis for every
case means that sensitivity and speciﬁcity for contrast
administration cannot be determined. For this reason,
a deﬁnitive diagnosis was available only for 2 of the
cases in which a lesion was observed only on contrast-
enhanced sequences. The ﬁnal diagnoses in the other 4
cases were suspected based upon the results of further
investigations and the subsequent disease course. How-
ever, the purpose of the present study was to mimic a
clinical situation and provide data to guide clinicians
at the time of imaging as to whether IV administration
of contrast media to patients with negative precontrast
imaging will increase the likelihood of identifying a
previously undetected lesion. Reviewer consensus on
the presence of a lesion was not determined at the end
of analysis in this study. Consideration was given to
any case in which either reviewer had identiﬁed a pre-
viously undetected lesion. This approach was used in
an attempt to present the most realistic scenario as to
the proportion of cases for which a lesion may be
missed should contrast not be administered. In this
study, there was only a single case for which both
reviewers independently identiﬁed a previously unde-
tected lesion (0.4%). This case appeared to represent a
false positive, with a ﬁnal diagnosis of feline idiopathic
epilepsy.
Although the results of this study are similar to those
reported in human medicine, conclusions can only be
drawn for low-ﬁeld brain MRI in dogs and cats.
Results may be dependent on magnetic ﬁeld strength
and sequence parameters.42,43 The use of contrast-
enhanced FLAIR images,44 digital subtraction images,
delayed image acquisition,14,45–47 diﬀerent doses47,48 or
other types of gadolinium-based contrast media49 also
may inﬂuence lesion detection. In this study, there was
no suggestion that the utility of postcontrast sequences
for lesion detection is dependent on low ﬁeld magnet
strength (0.2 T versus 0.23 T) or the use of diﬀerent
contrast agents (gadobenate dimeglumine versus gado-
butrol). A previous study in the human medical litera-
ture also concluded that whereas higher ﬁeld strength
magnets oﬀer greater lesion enhancement for a given
dose of gadolinium-based contrast media, this does not
result in a clinically relevant diﬀerence in lesion detec-
tion.50 The possibility that previous corticosteroid
administration could have resulted in a reduction in
blood-brain barrier permeability and thus decreased the
number of cases with observed contrast enhancement
also cannot be excluded.51,52
In conclusion, results of this study call into question
the IV administration of gadolinium-based contrast
agents to patients with a normal neurological examina-
tion and no visible lesion on precontrast imaging.
However, the authors recommend that contrast admin-
istration still be considered if there are persistent neu-
rological deﬁcits on examination consistent with the
presence of underlying pathology, such as CNS
inﬂammatory or neoplastic disease.
Footnotes
a Excel 2010; Microsoft Corp, Redmond, WA
b Esaote VetMR spa, Genova, Italy
c Esaote VetMR Grande, Genova, Italy
d MultiHance 0.5 mol/L, Bracco spa, Milan, Italy
e Gadovist 1 mol/L; Bayer plc, Newbury, Berkshire, UK
f Visbion, Surrey, UK
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